Cerivastatin이 혈중 근효소에 미치는 영향
- 김상현; 서창균; 조호찬; 이승현; 윤태성; 허지안; 조주현; 박재호
- Publication Year
- Aspartate transaminase; Cerivastatin; Creatine kinase; Lactate dehydrogenase
- Hypercholesterolemia is firmly established as a risk factor for the
development of atherosclerosis. Cerivastatin is a third generation statin, a synthetic
HMG-CoA reductase inhibitor which lowers plasma cholesterol level by
inhibiting endogenous cholesterol synthesis. It has also been reported that
cerivastatin is relatively well tolerated and has a low incidence of adverse effects.
It has been also reported that less than 1% of the patients treated with cerivastatin
experienced clinically significant elevation of muscle enzymes. The purpose
of this study was to investigate the effect of cerivastatin on serum muscle
enzymes. The patients with primary hypercholesterolemia were treated with statin
at least 4 weeks in Keimyung University Dongsan Medical Center. We compared
the effect of cerivastatin treatment (group A, 33 patients) on changes of muscle
enzymes including creatine kinase (CK), aspartate transaminase (AST) and lactate
dehydrogenase (LDH) with other statin treatment group (group B, 46
patients). The group A produced statistically significant elevation of CK and AST
(p<0.05) after treatment with cerivastatin when compared to the group B. More
than three fold elevation of CK level was developed only in the group A (p=0.02).
These results indicate that cerivastatin induces higher incidence of muscle
enzymes elevation than other statins.
- Authorize & License
- Files in This Item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.